Company: BIVIW
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001520138-25-000144
Chunk: 32

Company: BIOVIE INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 32
---
 paid for amounts included in the measurement of lease liabilities
were approximately $88,000 and $49,000 for the nine months ended March 31, 2025 and 2024, respectively.

The weighted average remaining lease term and discount
rate as of March 31, 2025 and June 30, 2024 were as follows:

    Schedule of weighted average remaining lease term and discount rate 

    March 31, 2025  
    June 30, 2024 

    Weighted average remaining lease term (Years) 

    Operating lease 
     3.8  
     4.6 
  
    Weighted average discount rate 

    Operating lease 
     15.00% 
     15.00%

     19 

    10.
    Commitments and Contingencies

Royalty Agreements

Pursuant to the Agreement and Plan of Merger entered
into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay
a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members,
PharmaIn Corporation, and The Barrett Edge, Inc.

Pursuant to the Technology Transfer Agreement entered
into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit
royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum
of $200,000 per year.

Shareholder class action complaint and shareholder derivative complaints

On January 19, 2024, a purported shareholder class action complaint,
captioned Eric Olmstead v. BioVie Inc. et al., No. 3:24-cv-00035, was filed in the U.S. District Court for the District of
Nevada, naming the Company   and certain of its officers as defendants. On February 22, 2024, a second, related putative securities
class action was filed in the same court asserting similar claims against the same defendants, captioned Way v. BioVie Inc. et al.,
No. 2:24-cv-00361. On April 15, 202